RESUMO
Mitochondria play a crucial role in the cell fate; in particular, reducing the accumulation of calcium in the mitochondrial matrix offers cardioprotection. This affect is achieved by a mild depolarization of the mitochondrial membrane potential, which prevents the assembly and opening of the mitochondrial permeability transition pore. For this reason, mitochondria are an attractive target for pharmacological interventions that prevent ischaemia/reperfusion injury. Isosteviol is a diterpenoid created from the acid hydrolysis of Steviarebaudiana Bertoni (fam. Asteraceae) glycosides that has shown protective effects against ischaemia/reperfusion injury, which are likely mediated through the activation of mitochondrial adenosine tri-phosphate (ATP)-sensitive potassium (mitoKATP) channels. Some triphenylphosphonium (triPP)-conjugated derivatives of isosteviol have been developed, and to evaluate the possible pharmacological benefits that result from these synthetic modifications, in this study, the mitochondriotropic properties of isosteviol and several triPP-conjugates were investigated in rat cardiac mitochondria and in the rat heart cell line H9c2. This study's main findings highlight the ability of isosteviol to depolarize the mitochondrial membrane potential and reduce calcium uptake by the mitochondria, which are typical functions of mitochondrial potassium channel openings. Moreover, triPP-conjugated derivatives showed a similar behavior to isosteviol but at lower concentrations, indicative of their improved uptake into the mitochondrial matrix. Finally, the cardioprotective property of a selected triPP-conjugated derivative was demonstrated in an in vivo model of acute myocardial infarct.
Assuntos
Diterpenos do Tipo Caurano/farmacologia , Mitocôndrias Cardíacas/efeitos dos fármacos , Mitocôndrias Cardíacas/metabolismo , Miócitos Cardíacos/efeitos dos fármacos , Miócitos Cardíacos/metabolismo , Compostos Organofosforados , Substâncias Protetoras/farmacologia , Animais , Modelos Animais de Doenças , Diterpenos do Tipo Caurano/química , Masculino , Potencial da Membrana Mitocondrial/efeitos dos fármacos , Traumatismo por Reperfusão Miocárdica/tratamento farmacológico , Traumatismo por Reperfusão Miocárdica/metabolismo , Traumatismo por Reperfusão Miocárdica/patologia , Compostos Organofosforados/química , Extratos Vegetais/química , Extratos Vegetais/farmacologia , Substâncias Protetoras/química , RatosRESUMO
The endogenous gasotransmitter hydrogen sulphide (H2S) is an important regulator of the cardiovascular system, particularly of myocardial function. Moreover, H2S exhibits cardioprotective activity against ischemia/reperfusion (I/R) or hypoxic injury, and is considered an important mediator of "ischemic preconditioning", through activation of mitochondrial potassium channels, reduction of oxidative stress, activation of the endogenous "anti-oxidant machinery" and limitation of inflammatory responses. Accordingly, H2S-donors, i.e. pro-drugs able to generate exogenous H2S, are viewed as promising therapeutic agents for a number of cardiovascular diseases. The novel H2S-donor 4-carboxy phenyl-isothiocyanate (4CPI), whose vasorelaxing effects were recently reported, was tested here in different experimental models of myocardial I/R. In Langendorff-perfused rat hearts subjected to I/R, 4CPI significantly improved the post-ischemic recovery of myocardial functional parameters and limited tissue injury. These effects were antagonized by 5-hydroxydecanoic acid (a blocker of mitoKATP channels). Moreover, 4CPI inhibited the formation of reactive oxygen species. We found the whole battery of H2S-producing enzymes to be present in myocardial tissue: cystathionine γ-lyase (CSE), cystathionine ß-synthase (CBS) and 3-mercaptopyruvate sulfurtransferase (MPST). Notably, 4CPI down-regulated the post-ischemic expression of CSE. In Langendorff-perfused mouse hearts, 4CPI reduced the post-ischemic release of norepinephrine and the incidence of ventricular arrhythmias. In both rat and mouse hearts, 4CPI did not affect the degranulation of resident mast cells. In isolated rat cardiac mitochondria, 4CPI partially depolarized the mitochondrial membrane potential; this effect was antagonized by ATP (i.e., the physiological inhibitor of KATP channels). Moreover, 4CPI abrogated calcium uptake in the mitochondrial matrix. Finally, in an in vivo model of acute myocardial infarction in rats, 4CPI significantly decreased I/R-induced tissue injury. In conclusion, H2S-donors, and in particular isothiocyanate-based H2S-releasing drugs like 4CPI, can actually be considered a suitable pharmacological option in anti-ischemic therapy.
Assuntos
Cardiotônicos/farmacologia , Sulfeto de Hidrogênio/metabolismo , Isotiocianatos/farmacologia , Traumatismo por Reperfusão Miocárdica/tratamento farmacológico , Estresse Oxidativo/efeitos dos fármacos , Canais de Potássio/metabolismo , Animais , Doenças Cardiovasculares/tratamento farmacológico , Doenças Cardiovasculares/metabolismo , Cistationina beta-Sintase/metabolismo , Cistationina beta-Sintase/farmacologia , Cistationina gama-Liase/metabolismo , Cisteína/análogos & derivados , Cisteína/farmacologia , Ácidos Decanoicos/farmacologia , Coração/efeitos dos fármacos , Hidroxiácidos/farmacologia , Masculino , Mastócitos/efeitos dos fármacos , Mastócitos/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Mitocôndrias Cardíacas/efeitos dos fármacos , Mitocôndrias Cardíacas/metabolismo , Infarto do Miocárdio/tratamento farmacológico , Infarto do Miocárdio/metabolismo , Isquemia Miocárdica/tratamento farmacológico , Isquemia Miocárdica/metabolismo , Traumatismo por Reperfusão Miocárdica/metabolismo , Ratos , Ratos Wistar , Espécies Reativas de Oxigênio/metabolismoRESUMO
Although there is a significant effort in the discovery of effective therapies to contrast both the pathological endocrine and metabolic aspects of diabetes and the endothelial dysfunction associated with this disease, no hypoglycemic drug has been proven to defeat the cardiovascular complications associated with type II diabetes. The aim of this research was to design new compounds exhibiting a double profile of hypoglycemic agents/NO-donors. The synthesis of molecules obtained by the conjunction of NO-donor moieties with two oral insulin-secretagogue drugs (repaglinide and nateglinide) was reported. NO-mediated vasorelaxing effects of the synthesized compounds were evaluated by functional tests on isolated endothelium-denuded rat aortic rings. The most potent molecule (4) was tested to evaluate the hypoglycemic and the anti-ischemic cardioprotective activities. This study indicates that 4 should represent a new insulin-secretagogue/NO-donor prodrug with an enhanced cardiovascular activity, which may contrast the pathological aspects of diabetes and endowed of cardioprotective activity.
Assuntos
Doenças Cardiovasculares/prevenção & controle , Diabetes Mellitus Tipo 2/tratamento farmacológico , Doadores de Óxido Nítrico/síntese química , Doadores de Óxido Nítrico/farmacologia , Animais , Cardiotônicos/síntese química , Cardiotônicos/farmacologia , Doenças Cardiovasculares/tratamento farmacológico , Doenças Cardiovasculares/etiologia , Diabetes Mellitus Tipo 2/complicações , Modelos Animais de Doenças , Hipoglicemiantes/síntese química , Hipoglicemiantes/farmacologia , Insulina/metabolismo , Secreção de Insulina , Masculino , Ratos , Ratos WistarRESUMO
Hydrogen sulfide is an endogenous pleiotropic gasotransmitter, which mediates important physiological effects in the human body. Accordingly, an impaired production of endogenous hydrogen sulfide contributes to the pathogenesis of important disorders. To date, exogenous compounds, acting as hydrogen sulfide-releasing agents, are viewed as promising pharmacotherapeutic agents. In a recent report, the hydrogen sulfide-releasing properties of some synthetic aryl isothiocyanate derivatives have been reported, indicating that the isothiocyanate function can be viewed as a suitable slow hydrogen sulfide-releasing moiety, endowed with the pharmacological potential typical of this gasotransmitter. Many isothiocyanate derivatives (deriving from a myrosinase-mediated transformation of glucosinolates) are well-known secondary metabolites of plants belonging to the family Brassicaceae, a large botanical family comprising many edible species. The phytotherapeutic and nutraceutic usefulness of Brassicaceae in the prevention of important human diseases, such as cancer, neurodegenerative processes and cardiovascular diseases has been widely discussed in the scientific literature. Although these effects have been largely attributed to isothiocyanates, the exact mechanism of action is still unknown. In this experimental work, we aimed to investigate the possible hydrogen sulfide-releasing capacity of some important natural isothiocyanates, studying it in vitro by amperometric detection. Some of the tested natural isothiocyanates exhibited significant hydrogen sulfide release, leading us to hypothesize that hydrogen sulfide may be, at least in part, a relevant player accounting for several biological effects of Brassicaceae.
Assuntos
Brassicaceae/química , Gasotransmissores/farmacocinética , Sulfeto de Hidrogênio/farmacocinética , Isotiocianatos/farmacologia , Gasotransmissores/química , Glucosinolatos/química , Glucosinolatos/farmacologia , Humanos , Sulfeto de Hidrogênio/química , Isotiocianatos/químicaRESUMO
Endothelial dysfunction and consequent reduction of biosynthesis of endogenous nitric oxide (NO) play an important pathogenetic role in the cardiovascular complications associated with type II diabetes. In this work, the hybrid drugs 3a and 3b, nitrooxymethylbenzoate-derivatives of 1 (which is a hydroxylated active metabolite of glibenclamide 2), are reported. The pharmacodynamic characterization of 3b showed that its hypoglycaemic activity is enriched with additional NO-donor effects, conferring vasorelaxing and anti-platelet properties of potentially great usefulness for diabetes-related cardiovascular disorders.
Assuntos
Diabetes Mellitus Tipo 2/tratamento farmacológico , Glibureto/uso terapêutico , Hipoglicemiantes/uso terapêutico , Doadores de Óxido Nítrico/uso terapêutico , Inibidores da Agregação Plaquetária/uso terapêutico , Vasodilatadores/uso terapêutico , Animais , Aorta/efeitos dos fármacos , Diabetes Mellitus Tipo 2/induzido quimicamente , Glibureto/química , Glibureto/farmacologia , Humanos , Hipoglicemiantes/química , Hipoglicemiantes/farmacologia , Insulina/metabolismo , Ilhotas Pancreáticas/metabolismo , Fígado/metabolismo , Masculino , Músculo Liso Vascular/efeitos dos fármacos , Músculo Liso Vascular/metabolismo , Óxido Nítrico/metabolismo , Doadores de Óxido Nítrico/química , Doadores de Óxido Nítrico/farmacologia , Inibidores da Agregação Plaquetária/química , Inibidores da Agregação Plaquetária/farmacologia , Ratos , Ratos Wistar , Vasodilatadores/química , Vasodilatadores/farmacologiaRESUMO
BACKGROUND: Mitochondria play a central role in ATP-generating processes. Indeed, in mammalian tissues, up to 90% of ATP is generated by mitochondria through the process of oxidative phosphorylation; furthermore, mitochondria are involved in multiple signal transduction pathways. A rapidly expanding body of literature has confirmed that mitochondria play a pivotal role in apoptosis, cardio- and neuro-protection, and various neurodegenerative disorders, ranging from Parkinson's to Alzheimer's disease. Mitochondria are also the targets of multiple drugs, some of these are specifically designed to affect mitochondrial function, while others have primary targets in other cellular locations but may interact with mitochondria because of the presence of numerous targets on this organelle. In this regard, mitochondrial potassium (mitoK) channels play a critical role in mitochondrial function and, consequently, in the metabolism of the whole cell. OBJECTIVE: To describe mitoK channels from a structural point of view and investigate their pathophysiological roles, focusing on possible specific modulators that might be useful as pharmacological tools in the treatment of various pathologies characterized by mitoK involvement. RESULTS: mitoK channels play a decisive role in several pathologies, including cardiovascular diseases, particularly in myocardial infarction and neurodegenerative diseases, and they are emerging as promising oncological targets. CONCLUSIONS: mitoK channels represent novel targets, and mitoK channel modulators represent an exciting tool for pharmacological intervention against such pathological conditions.
Assuntos
Mitocôndrias/metabolismo , Bloqueadores dos Canais de Potássio/metabolismo , Canais de Potássio/metabolismo , Trifosfato de Adenosina , Benzopiranos/química , Benzopiranos/metabolismo , Benzopiranos/uso terapêutico , Cálcio/metabolismo , Humanos , Infarto do Miocárdio/tratamento farmacológico , Infarto do Miocárdio/metabolismo , Infarto do Miocárdio/fisiopatologia , Doenças Neurodegenerativas/tratamento farmacológico , Doenças Neurodegenerativas/metabolismo , Doenças Neurodegenerativas/fisiopatologia , Bloqueadores dos Canais de Potássio/química , Bloqueadores dos Canais de Potássio/uso terapêutico , Canais de Potássio/química , Espécies Reativas de Oxigênio/metabolismoRESUMO
In the last four decades, the several classes of diuretics, currently available for clinical use, have been the first line option for the therapy of widespread cardiovascular and non-cardiovascular diseases. Diuretic drugs generally exhibit an overall favourable risk/benefit balance. However, they are not devoid of side effects. In particular, all the classes of diuretics cause alteration of potassium homeostasis. In recent years, understanding of the physiological role of the renal outer medullary potassium (ROMK) channels, has shown an intriguing pharmacological target for developing an innovative class of diuretic agents: the ROMK inhibitors. This novel class is expected to promote diuretic activity comparable to (or even higher than) that provided by the most effective drugs used in clinics (such as furosemide), with limited effects on potassium homeostasis. In this review, the physio-pharmacological roles of ROMK channels in the renal function are reported, along with the most representative molecules which have been currently developed as ROMK inhibitors.
Assuntos
Diuréticos/química , Rim/metabolismo , Canais de Potássio Corretores do Fluxo de Internalização/metabolismo , Benzofuranos/química , Benzofuranos/metabolismo , Benzofuranos/farmacologia , Diuréticos/metabolismo , Diuréticos/farmacologia , Compostos Heterocíclicos com 1 Anel/química , Compostos Heterocíclicos com 1 Anel/metabolismo , Compostos Heterocíclicos com 1 Anel/farmacologia , Humanos , Rim/efeitos dos fármacos , Piperazinas/química , Piperazinas/metabolismo , Piperazinas/farmacologia , Potássio/metabolismo , Canais de Potássio Corretores do Fluxo de Internalização/antagonistas & inibidores , Canais de Potássio Corretores do Fluxo de Internalização/química , Sódio/metabolismo , Simportadores/química , Simportadores/metabolismoRESUMO
Large-conductance calcium-activated potassium channels (BK) of smooth muscle play a role in the relevant modulation of vascular tone, due to their calcium- and voltage-dependent mechanisms of activation. A potential role of endothelial BK channels has also been suggested by approaches on endothelial cell cultures. However, no functional study, aimed at evaluating the contribution of endothelial BK channels to the effect of BK-openers, has been reported. Resveratrol and NS 1619, BK-openers, have been tested on endothelium-intact and -denuded aortic rings. Furthermore, the effects of high depolarisation of potassium channel blockers TEA (Tetraethylammonium), 4-AP ( 4-Aminopyridine) and IbTX (Iberiotoxin) and of inhibitors of NO-pathway (L-NAME and ODQ) have been evaluated. The presence of endothelium increased the vasorelaxing potency of BK-openers. This potentiation was eliminated by L-NAME and ODQ. TEA, 4-AP, IbTX and high depolarisation had modest or no antagonist influence on resveratrol in endothelium-denuded aortic rings. The effects of NS 1619 on endothelium-denuded aortic rings were not affected by IbTX, and were modestly antagonised by TEA, 4-AP and high depolarisation. In intact endothelium vessels, TEA, IbTX and 4-AP antagonised the vasorelaxing effect of the two BK-activators. A BK-mediated release of endothelial NO seems a very important factor, determining a strong influence on vasodilator profile of BK-openers. Therefore, an eventual therapy with a BK-opener could promote a series of cardiovascular impacts not confined to the only direct vasorelaxing effects, but also due to a significant contribution of endothelial NO.
Assuntos
Aorta Torácica/efeitos dos fármacos , Benzimidazóis/farmacologia , Endotélio Vascular/fisiologia , Canais de Potássio Ativados por Cálcio de Condutância Alta/agonistas , Estilbenos/farmacologia , Vasodilatação/efeitos dos fármacos , 4-Aminopiridina/farmacologia , Animais , Aorta Torácica/metabolismo , Aorta Torácica/fisiologia , Bloqueadores dos Canais de Cálcio/farmacologia , Relação Dose-Resposta a Droga , Inibidores Enzimáticos/farmacologia , Técnicas In Vitro , Canais de Potássio Ativados por Cálcio de Condutância Alta/antagonistas & inibidores , Canais de Potássio Ativados por Cálcio de Condutância Alta/fisiologia , Masculino , NG-Nitroarginina Metil Éster/farmacologia , Óxido Nítrico/metabolismo , Oxidiazóis/farmacologia , Peptídeos/farmacologia , Cloreto de Potássio/farmacologia , Quinoxalinas/farmacologia , Ratos , Ratos Wistar , Resveratrol , Tetraetilamônio/farmacologia , Vasodilatadores/farmacologiaRESUMO
In our previous study, RAPD (Random Amplified Polymorphic DNA) analysis revealed species-specific markers for three medicinal Echinacea species (Asteraceae): E. angustifolia DC., E. pallida (Nutt.) Nutt. and E. purpurea (L.) Moench. In the present work, we have converted a RAPD marker (750 bp) for E. purpurea into a SCAR (Sequence Characterized Amplified Region) marker. SCAR-PCR, in fact, revealed the expected amplicon (330 bp) only in E. purpurea and not in the other two species, giving further evidence for differences in medicinal Echinacea spp. genome and confirming a greater similarity between E. pallida and angustifolia.
Assuntos
DNA de Plantas/análise , Echinacea/genética , Fitoterapia , Primers do DNA , Echinacea/classificação , Humanos , Técnica de Amplificação ao Acaso de DNA PolimórficoRESUMO
This study was aimed at evaluating, on a limited number of benzopyran compounds, whether the insertion of an electron-rich spirocyclic substituent at the C4 carbon of the benzopyran molecular nucleus may improve the cardioprotective properties against ischemia. Some of the new compounds (1b, 2b, and 4b) exhibited interesting anti-ischemic properties without affecting significantly the blood pressure parameters.
Assuntos
Trifosfato de Adenosina/farmacologia , Benzopiranos/farmacologia , Cardiotônicos/farmacologia , Isquemia/tratamento farmacológico , Mitocôndrias Cardíacas/efeitos dos fármacos , Traumatismo por Reperfusão Miocárdica/tratamento farmacológico , Canais de Potássio/efeitos dos fármacos , Animais , Aorta/efeitos dos fármacos , Benzopiranos/síntese química , Benzopiranos/química , L-Lactato Desidrogenase/metabolismo , Mitocôndrias Cardíacas/metabolismo , Ratos , Vasodilatação/efeitos dos fármacosRESUMO
In a preliminary work, we reported two NO-sartans, possessing the characteristics of an AT(1) antagonist and a "slow NO donor", obtained by adding NO-donor side chains to losartan 1. The NO release from an NO-sartan should be modulated in order to strengthen the antihypertensive activity of the native drug and to ensure additional effects, such as the antiplatelet and anti-ischemic ones. To obtain a collection of prototypical NO-sartans, showing different rates of NO release, new NO-donor moieties have been linked to 1 or its active metabolite 2 (EXP 3174). Almost all the synthesized compounds exhibited both AT(1)-antagonist and NO-mediated vasorelaxing properties, with a wide range of NO-releasing rates. Further pharmacological investigation on compound 4a showed that it possessed antihypertensive and cardiac antihypertrophic effects similar to those of the reference AT(1)-blocking or ACE-inhibiting drugs. Furthermore, the additional anti-ischemic cardio-protective properties and antiplatelet effects of 4a have been preliminarily investigated.
Assuntos
Bloqueadores do Receptor Tipo 1 de Angiotensina II , Anti-Hipertensivos , Losartan , Receptor Tipo 1 de Angiotensina/efeitos dos fármacos , Bloqueadores do Receptor Tipo 1 de Angiotensina II/síntese química , Bloqueadores do Receptor Tipo 1 de Angiotensina II/metabolismo , Bloqueadores do Receptor Tipo 1 de Angiotensina II/farmacologia , Animais , Anti-Hipertensivos/síntese química , Anti-Hipertensivos/metabolismo , Anti-Hipertensivos/farmacologia , Desenho de Fármacos , Avaliação Pré-Clínica de Medicamentos , Hipertensão/tratamento farmacológico , Técnicas In Vitro , Losartan/síntese química , Losartan/metabolismo , Losartan/farmacologia , Masculino , Estrutura Molecular , Ratos , Ratos Wistar , Receptor Tipo 1 de Angiotensina/metabolismo , Relação Estrutura-Atividade , Fatores de TempoRESUMO
INTRODUCTION: Hydrogen sulfide (H2S) is an endogenous gasotransmitter, involved in the regulation of several biological functions. Conversely, impaired biosynthesis of H2S is associated with important diseases. This paves the way for exciting pharmacological perspectives for drugs acting on the 'H2S system'. AREAS COVERED: At the beginning of this manuscript, the authors present the biological roles and mechanisms of action of hydrogen sulfide. The authors then discuss the developments in the modulation of the H2S system via heterogeneous molecules, which behave as sources of exogenous H2S, and are promising drugs for a number of diseases. EXPERT OPINION: The rate of H2S generation, the physicochemical characteristics and the bioavailability greatly affect the overall pharmacological profile of each H2S-releasing compound. Therefore, the development of broad collections of original moieties endowed with heterogeneous rates/mechanisms of H2S release and a variety of physicochemical, biological and pharmacological features is the most timely and compelling issue in the field of H2S-based drug discovery.
Assuntos
Desenho de Fármacos , Descoberta de Drogas/métodos , Sulfeto de Hidrogênio/metabolismo , Animais , Humanos , FarmacologiaRESUMO
OBJECTIVE: This study was aimed at investigating whether the ß2 -adrenoceptor agonist, salbutamol, could modulate RhoA activation in normal and homologously desensitized bronchial smooth muscle cells (BSMC). METHODS: Serum-starved BSMCs were stimulated with the Rho-activating compound calpeptin in the presence or absence of salbutamol, the Epac activator, 8-pCPT-2'-O-Me-cAMP, or the site-selective activator of cAMP-dependent protein kinase A (PKA), 6-Bnz-cAMP. Activated RhoA was assessed by immunocytochemical detection and by RhoA G-LISA assay. KEY FINDINGS: Stimulation with calpeptin caused translocation of RhoA from cytosol to plasma membrane, a condition required for the functional coupling of RhoA with its cellular targets. Pretreatment with salbutamol 10 µm for 15 min was found to block calpeptin-induced activation of RhoA in normal, but not in homologously desensitized cells. Pretreatment of calpeptin-stimulated BSMC with 8-pCPT-2'-O-Me-cAMP or 6-Bnz-cAMP could reproduce the effect of salbutamol. CONCLUSIONS: These findings demonstrated that salbutamol inhibits RhoA activation in human BSMC through ß2 -adrenoceptor/Epac/PKA pathway. An important pharmacological implication of these finding is the possible contribution of RhoA pathway to the molecular mechanism involved in airway smooth muscle relaxation caused by acute/chronic exposure to ß2-adrenoceptor agonists.
Assuntos
Agonistas de Receptores Adrenérgicos beta 2/farmacologia , Albuterol/farmacologia , Brônquios/efeitos dos fármacos , Miócitos de Músculo Liso/efeitos dos fármacos , Agonistas de Receptores Adrenérgicos beta 2/administração & dosagem , Albuterol/administração & dosagem , Brônquios/citologia , Linhagem Celular , Membrana Celular/metabolismo , AMP Cíclico/análogos & derivados , AMP Cíclico/farmacologia , Citosol/metabolismo , Dipeptídeos/farmacologia , Humanos , Dados de Sequência Molecular , Miócitos de Músculo Liso/metabolismo , Proteína rhoA de Ligação ao GTP/metabolismoRESUMO
Aggressive behavior and diffuse infiltrative growth are the main features of Glioblastoma multiforme (GBM), together with the high degree of resistance and recurrence. Evidence indicate that GBM-derived stem cells (GSCs), endowed with unlimited proliferative potential, play a critical role in tumor development and maintenance. Among the many signaling pathways involved in maintaining GSC stemness, tumorigenic potential, and anti-apoptotic properties, the PDK1/Akt pathway is a challenging target to develop new potential agents able to affect GBM resistance to chemotherapy. In an effort to find new PDK1/Akt inhibitors, we rationally designed and synthesized a small family of 2-oxindole derivatives. Among them, compound 3 inhibited PDK1 kinase and downstream effectors such as CHK1, GS3Kα and GS3Kß, which contribute to GCS survival. Compound 3 appeared to be a good tool for studying the role of the PDK1/Akt pathway in GCS self-renewal and tumorigenicity, and might represent the starting point for the development of more potent and focused multi-target therapies for GBM.
Assuntos
Desenho de Fármacos , Glioblastoma/tratamento farmacológico , Indóis/farmacologia , Inibidores de Proteínas Quinases/farmacologia , Proteínas Serina-Treonina Quinases/antagonistas & inibidores , Proteínas Proto-Oncogênicas c-akt/antagonistas & inibidores , Transdução de Sinais/efeitos dos fármacos , Contagem de Células , Diferenciação Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Glioblastoma/patologia , Humanos , Indóis/síntese química , Indóis/química , Estrutura Molecular , Oxindóis , Inibidores de Proteínas Quinases/síntese química , Inibidores de Proteínas Quinases/química , Proteínas Serina-Treonina Quinases/metabolismo , Proteínas Proto-Oncogênicas c-akt/metabolismo , Piruvato Desidrogenase Quinase de Transferência de Acetil , Relação Estrutura-AtividadeRESUMO
The aim of this work was to develop lead pharmacodynamic hybrids, NO-sartans, possessing the characteristics of a typical AT1-antagonist and of a "slow NO donor", by adding NO-donor side chains to losartan. These new compounds, 2a and 2b, displayed vasorelaxing effects, due to the release of NO, and antagonized the vasocontractile effects of angiotensin II, with potency values similar to that of losartan. In vivo, the antihypertensive effects of 2a were similar to those of losartan and captopril.
Assuntos
Bloqueadores do Receptor Tipo 1 de Angiotensina II/síntese química , Anti-Hipertensivos/síntese química , Losartan/análogos & derivados , Losartan/síntese química , Vasodilatadores/síntese química , Bloqueadores do Receptor Tipo 1 de Angiotensina II/química , Bloqueadores do Receptor Tipo 1 de Angiotensina II/farmacologia , Animais , Anti-Hipertensivos/farmacologia , Pressão Sanguínea/efeitos dos fármacos , Losartan/farmacologia , Ratos , Ratos Endogâmicos SHR , Relação Estrutura-Atividade , Vasodilatadores/farmacologiaRESUMO
Serum homocysteine (sHcy) has been found to be elevated in patients with type 2 diabetes mellitus, as well as in other clinical conditions associated with insulin resistance and/or vascular diseases. The aims of this study were to measure the relationship between sHcy with biohumoral markers of insulin resistance in pregnant women affected with gestational diabetes mellitus (GDM). We studied 2 groups of pregnant women categorized, after a 100-g, 3-hour oral glucose tolerance test (OGTT) as nondiabetic (n = 78) or affected with GDM (n = 15), by measuring sHcy, serum folate, albumin, vitamin B(12), uric acid, and lipids. In both groups, peripheral insulin sensitivity was measured by using the OGTT-derived index of Matsuda and DeFronzo (ISI(OGTT)). Serum homocysteine was significantly higher in the group with GDM compared with nondiabetic women (5.88 +/- 2.26 micromol/L v 4.45 +/- 1.52 micromol/L; P =.003); was inversely related to serum folate (r = -.48; P =.0001), and was significantly related to serum albumin (r =.27; P =.009), 2-hour plasma glucose (r =.25; P =.01), as well as to serum uric acid (r =.23; P =.03). No relationship was observed between sHcy and serum vitamin B(12), serum triglycerides, total, or high-density lipoprotein (HDL) cholesterol, mean blood pressure and ISI(OGTT). Vitamin B(12) was correlated with ISI(OGTT) (r =.36; P =.0005) and inversely with mean blood pressure (r = -.24; P =.02). GDM remained significantly associated with higher sHcy concentrations also after adjusting for age, serum folate, albumin, uric acid, ISI(OGTT), and vitamin B(12) (P =.006). In conclusion, we found that sHcy is significantly increased in women with GDM, independently of other confounding variables, is significantly related to 2-hour OGTT plasma glucose, and seems unrelated to insulin resistance in these subjects.
Assuntos
Diabetes Gestacional/sangue , Homocisteína/sangue , Adulto , Glicemia/análise , Pressão Sanguínea , Estudos de Casos e Controles , Diabetes Gestacional/diagnóstico , Diabetes Gestacional/fisiopatologia , Feminino , Ácido Fólico/sangue , Teste de Tolerância a Glucose , Humanos , Masculino , Gravidez , Albumina Sérica/análise , Ácido Úrico/sangue , Vitamina B 12/sangueRESUMO
Hydrogen sulfide (H2S) is an endogenous gasotransmitter, which mediates important physiological effects in the cardiovascular system. Accordingly, an impaired production of endogenous H2S contributes to the pathogenesis of important cardiovascular disorders, such as hypertension. Therefore, exogenous compounds, acting as H2S-releasing agents, are viewed as promising pharmacotherapeutic agents for cardiovascular diseases. Thus, this paper aimed at evaluating the H2S-releasing properties of some aryl isothiocyanate derivatives and their vascular effects. The release of H2S was determined by amperometry, spectrophotometry and gas/mass chromatography. Moreover, the vascular activity of selected isothiocyanates were tested in rat conductance (aorta) and coronary arteries. Since H2S has been recently reported to act as an activator of vascular Kv7 potassium channels, the possible membrane hyperpolarizing effects of isothiocyanates were tested on human vascular smooth muscle (VSM) cells by spectrofluorescent dyes. Among the tested compounds, phenyl isothiocyanate (PhNCS) and 4-carboxyphenyl isothiocyanate (PhNCS-COOH) exhibited slow-H2S-release, triggered by organic thiols such as L-cysteine. These compounds were endowed with vasorelaxing effects on conductance and coronary arteries. Moreover, these two isothiocyanates caused membrane hyperpolarization of VSM cells. The vascular effects of isothiocyanates were strongly abolished by the selective Kv7-blocker XE991. In conclusion, the isothiocyanate function can be viewed as a suitable slow H2S-releasing moiety, endowed with vasorelaxing and hypotensive effects, typical of this gasotransmitter. Thus, such a chemical moiety can be employed for the development of novel chemical tools for basic studies and promising cardiovascular drugs.
Assuntos
Sulfeto de Hidrogênio/farmacologia , Isotiocianatos/farmacologia , Músculo Liso Vascular/efeitos dos fármacos , Animais , Aorta/efeitos dos fármacos , Aorta/fisiologia , Relação Dose-Resposta a Droga , Técnicas In Vitro , Masculino , Músculo Liso Vascular/fisiologia , Ratos , Ratos Wistar , Vasoconstrição/efeitos dos fármacos , Vasodilatação/efeitos dos fármacosRESUMO
OBJECTIVE: Flavonoids are important components of 'functional foods', with beneficial effects on the cardiovascular function, mainly due to their antioxidant activity. Many flavonoids exert antihypertensive, anti-atherosclerotic and antiplatelet activity and positive effects against endothelial dysfunction. Recent evidence indicates that they exert cardioprotective effects against myocardial ischaemia/reperfusion (I/R) injury. The aim of this work was to investigate these properties for flavonoids with different structural characteristics. METHODS: In this work, the cardioprotective effects of eight flavonoids endowed with different structural characteristics were tested on Langendorff-perfused rat hearts submitted to 30 min of global ischaemia followed by 120 min of reperfusion (I/R). KEY FINDINGS: Only the 5-hydroxy-substituted derivatives, such as 5-hydroxy flavone, apigenin, chrysin and naringenin, conferred on the hearts an improved post-ischaemic functional recovery associated with lower extension of tissue injury. A similar pharmacological profile was exhibited by 5-methoxy flavone. In contrast, 6-hydroxy flavone, 7-hydroxy flavone and 4'-hydroxy flavanone did not confer significant protection against the injury induced by I/R. CONCLUSIONS: Some flavonoids exhibit direct cardioprotective effects against the injury induced by drastic I/R and this pharmacological property seems to be related to their structural characteristics. Such an influence of structural requirements seems to indicate that the cardioprotective effects may be due to the interaction with specific pharmacological targets.
Assuntos
Fármacos Cardiovasculares/uso terapêutico , Flavonoides/uso terapêutico , Coração/efeitos dos fármacos , Infarto do Miocárdio/tratamento farmacológico , Traumatismo por Reperfusão Miocárdica/prevenção & controle , Miocárdio/patologia , Extratos Vegetais/uso terapêutico , Animais , Fármacos Cardiovasculares/farmacologia , Flavonas/farmacologia , Flavonas/uso terapêutico , Flavonoides/farmacologia , Coração/fisiopatologia , Masculino , Contração Miocárdica/efeitos dos fármacos , Infarto do Miocárdio/fisiopatologia , Traumatismo por Reperfusão Miocárdica/fisiopatologia , Fitoterapia , Extratos Vegetais/farmacologia , Ratos , Ratos WistarRESUMO
This study was aimed at investigating the antitumor activity of novel 2-oxindole derivatives against a well-characterized human nonsmall cell lung cancer (NSCLC) cell line. Test compounds produced an antiproliferative activity in the low micromolar/submicromolar range of concentrations and significantly induced typical apoptotic morphology with cell shrinkage, nuclear condensation and fragmentation, and rupture of cells into debris in a relatively low percentage of A549 cells. Cell cycle arrest occurred at the G1/S phase (1a and 2), and Akt phosphorylation was significantly inhibited at Thr308 and Ser473. The most active compound (1a) has an IC50 6-fold lower than the Akt inhibitor, perifosine. These data suggest that the new compounds may be cytostatic and may have maximum clinical effects in NSCLC patients who do not respond to EGFR inhibitors. These findings prompt us to further explore the oxindole structure as leading scaffold to design new molecules with potent antitumor activity against NSCLC.
RESUMO
A small library of arylthioamides 1-12 was easily synthesized, and their H2S-releasing properties were evaluated both in the absence or in the presence of an organic thiol such as l-cysteine. A number of arylthioamides (1-3 and 7) showed a slow and l-cysteine-dependent H2S-releasing mechanism, similar to that exhibited by the reference slow H2S-releasing agents, such as diallyl disulfide (DADS) and the phosphinodithioate derivative GYY 4137. Compound 1 strongly abolished the noradrenaline-induced vasoconstriction in isolated rat aortic rings and hyperpolarized the membranes of human vascular smooth muscle cells in a concentration-dependent fashion. Finally, a significant reduction of the systolic blood pressure of anesthetized normotensive rats was observed after its oral administration. Altogether these results highlighted the potential of arylthioamides 1-3 and 7 as H2S-donors for basic studies, and for the rational design/development of promising pharmacotherapeutic agents to treat cardiovascular diseases.